Cargando…

Marked Increase in Avidity of SARS-CoV-2 Antibodies 7–8 Months After Infection Is Not Diminished in Old Age

The kinetics of immunoglobulin G (IgG) avidity maturation during severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection obtained from 217 participants of the Ischgl cohort, Austria, was studied 0.5–1.5 months (baseline) and 7–8 months (follow-up) after infection. The IgG avidity assa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pichler, Daniel, Baumgartner, Matthias, Kimpel, Janine, Rössler, Annika, Riepler, Lydia, Bates, Katie, Fleischer, Verena, von Laer, Dorothee, Borena, Wegene, Würzner, Reinhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195195/ https://www.ncbi.nlm.nih.gov/pubmed/34086960 http://dx.doi.org/10.1093/infdis/jiab300

Ejemplares similares

Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
por: Rössler, Annika, et al.
Publicado: (2022)

Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination
por: Harthaller, Teresa, et al.
Publicado: (2023)

Comparison of Four SARS-CoV-2 Neutralization Assays
por: Riepler, Lydia, et al.
Publicado: (2020)

Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
por: Borena, Wegene, et al.
Publicado: (2021)

Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl
por: Borena, Wegene, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
por: Willeit, Peter, et al.
Publicado: (2022)

Reduced sensitivity of antibody tests after omicron infection
por: Rössler, Annika, et al.
Publicado: (2023)

High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl
por: Knabl, Ludwig, et al.
Publicado: (2021)

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
por: Rössler, Annika, et al.
Publicado: (2023)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
por: Bánki, Zoltán, et al.
Publicado: (2022)

Measles Elimination: Identifying Susceptible Sub-Populations to Tailor Immunization Strategies
por: Kreidl, Peter, et al.
Publicado: (2019)

High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz
por: Harthaller, Teresa, et al.
Publicado: (2022)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
por: Rössler, Annika, et al.
Publicado: (2022)

12-month SARS-CoV-2 antibody persistency in a Tyrolean COVID-19 cohort
por: Deisenhammer, Florian, et al.
Publicado: (2021)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria
por: Bánki, Zoltán, et al.
Publicado: (2022)

14-year-old Schoolchildren can Consent to Get Vaccinated in Tyrol, Austria: What do They know about Diseases and Vaccinations?
por: Kreidl, Peter, et al.
Publicado: (2020)

Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
por: Seekircher, Lisa, et al.
Publicado: (2023)

Factors affecting HPV vaccine acceptance in west Austria: Do we need to revise the current immunization scheme?
por: Borena, Wegene, et al.
Publicado: (2016)

Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
por: Paetzold, Jörg, et al.
Publicado: (2022)

Successful return to professional men’s football (soccer) competition after the COVID-19 shutdown: a cohort study in the German Bundesliga
por: Meyer, Tim, et al.
Publicado: (2021)

Prevalence of SARS-CoV-2 IgG antibodies in a large prospective cohort study of elite football players in Germany (May–June 2020): implications for a testing protocol in asymptomatic individuals and estimation of the rate of undetected cases
por: Mack, Dietrich, et al.
Publicado: (2021)

No molecular or serological evidence of Zikavirus infection among healthy blood donors living in or travelling to regions where Aedes albopictus circulates
por: Borena, Wegene, et al.
Publicado: (2017)

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
por: Koske, Iris, et al.
Publicado: (2019)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

The Role of HPV and Non-HPV Sexually Transmitted Infections in Patients with Oropharyngeal Carcinoma: A Case Control Study
por: Kofler, Barbara, et al.
Publicado: (2020)

6-month SARS-CoV-2 antibody persistency in a Tyrolian COVID-19 cohort
por: Deisenhammer, Florian, et al.
Publicado: (2020)

Post-Treatment HPV Surface Brushings and Risk of Relapse in Oropharyngeal Carcinoma
por: Kofler, Barbara, et al.
Publicado: (2020)

Can high COVID-19 vaccination rates in adults help protect unvaccinated children? Evidence from a unique mass vaccination campaign, Schwaz/Austria, March 2021
por: Winner, Hannes, et al.
Publicado: (2022)

Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants
por: Volland, André, et al.
Publicado: (2021)

Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity
por: Nakagama, Yu, et al.
Publicado: (2022)

Fcγ Receptor Type I (CD64)-Mediated Impairment of the Capacity of Dendritic Cells to Activate Specific CD8 T Cells by IgG-opsonized Friend Virus
por: Bánki, Zoltán, et al.
Publicado: (2019)

Estimating seroprevalence of SARS-CoV-2 antibodies using three self-reported symptoms: development of a prediction model based on data from Ischgl, Austria
por: Lehmann, Jens, et al.
Publicado: (2021)

Factors affecting children’s HPV vaccination in Austria: Evidence from a parent survey
por: Waser, Madeleine, et al.
Publicado: (2022)

Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria
por: Borena, Wegene, et al.
Publicado: (2016)

Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections
por: Singh, Gagandeep, et al.
Publicado: (2023)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020
por: Siller, Anita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_45u072bi447nj9dh8ojsg1n62r